Sectoral Asset Management Inc.

Institutional manager·CIK 0001274413
Latest Qtr return
+61.8%
SPY latest qtr
+17.6%
Alpha
+44.2ptsvs SPY
Invested
$120.7M
Holdings
77
Trades YTD
0

Performance · Fund vs SPY

Cumulative return · quarterly snapshots
-20%+0%+75%Sectoral +55.9%SPY +72.2%Q1 '25Q2 '25Q3 '25Q4 '25

Coverage 98%. 4 quarters of 2025 measured against SPY adj-close benchmark.

EDITORIAL BRIEF · refreshed Jul 2, 2026

Why follow Sectoral Asset Management Inc. right now?

Sectoral Asset Management's Q1 2026 13F-HR shows a $121M healthcare-specialist portfolio across 77 positions, with notable concentration at the top: EVOMMUNE INC (11.2%) and CONTINEUM THERAPEUTICS (7.9%) together account for nearly one-fifth of reported assets. Small- and mid-cap clinical-stage names dominate the upper weights alongside large-caps LLY, JNJ, and GILD. Quarter-over-quarter share counts rose sharply in ARS PHARMACEUTICALS (+166%), INSMED (+76%), and GILEAD (+54%), per the filing's comparative data.

Reported quarterly returns of +61.8% (Q1 2026) and +55.1% (Q4 2025) produced alpha of +44.2 and +37.4 percentage points respectively against SPY, following a -6.6% quarter in Q2 2025. Past performance is not indicative of future results.

Generated from public SEC filings. Not investment advice.…

Read the full 114-word brief. Pro members get the complete editorial analysis on every curated manager, plus Sunday Pulse + Stock Picks.

Unlock with Pro — $9.99/mo

Top holdings · current snapshot

Source: 13F-HR
01
$EVMN
EVOMMUNE INC
Held since at least Q1 2024
11.2%
-0.0%
~$22.99 Mar 2026
02
$CTNM
CONTINEUM THERAPEUTICS
Q4 2025: Sold 9.1% (800.8k → 727.6k shares)
7.9%
-0.8%
~$13.06 Mar 2026
03
$SI
SHOULDER INNOVATIONS
Q4 2025: Sold 12.6% (492.4k → 430.4k shares)
5.2%
+1.2%
~$14.53 Mar 2026
04
$LLY
ELI LILLY & CO
Q4 2025: Sold 12.7% (7.3k → 6.4k shares)
4.8%
+20.1%
~$919.77 Mar 2026
05
$JNJ
JOHNSON & JOHNSON
Q4 2025: Sold 10.3% (20.3k → 18.2k shares)
3.7%
-7.8%
~$244.44 Mar 2026
06
$GILD
GILEAD SCIENCES INC
Q4 2025: Increased +53.7% (17.9k → 27.5k shares)
3.4%
-10.6%
~$150.30 Mar 2026
07
$UNH
UNITEDHEALTH GRP INC
Q4 2025: Increased +10.0% (13.6k → 15.0k shares)
3.4%
+40.5%
~$270.59 Mar 2026
08
$AMGN
AMGEN INC
Q4 2025: Sold 29.5% (13.1k → 9.2k shares)
2.9%
-9.1%
~$381.65 Mar 2026
09
$VRTX
VERTEX PHARMA
Q4 2025: Sold 12.5% (8.0k → 7.0k shares)
2.9%
-9.3%
~$493.38 Mar 2026
10
$INSM
INSMED INC
Q4 2025: Increased +75.9% (11.2k → 19.7k shares)
2.8%
-37.8%
~$171.89 Mar 2026
See all 77 holdings · Pro →

Recent trades · Last 90 days

No Form 4 / 13D / 13G trade events on file in the recent window. 13F filers report position snapshots quarterly rather than per-trade events, so this section is most useful for managers who also file Form 4 or 13D/G.

Convergence · Sectoral Asset Management Inc.

active pattern signal
Pattern 01 · Convergence · all signals →
AMGN
Amgen Inc. - Common Stock 16 curated funds · 1 Congress  · 30-day window  · 2026-06-05 – 2026-07-05

Pattern cards reflect public SEC EDGAR and Congressional filing data only. Detection uses filing dates; trade execution dates may differ. Past convergence patterns do not predict future returns. Nothing here is investment advice.

Source data: SEC EDGAR · 13F-HR filings · Performance through 2026-03-31 · Last refreshed 13:33 UTC.